Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Garofalo Health Care S.p.A. is a leading Italian private accredited healthcare group, listed on the Euronext STAR segment of the Italian Stock Exchange and headquartered in Rome. Founded in the 1950s by surgeon Raffaele Garofalo, it has grown into the first and only publicly listed private healthcare company in Italy, operating 37-38 centers of excellence across eight prosperous regions in Northern and Central Italy, including Piedmont, Lombardy, Veneto, Friuli Venezia Giulia, Liguria, Emilia Romagna, Tuscany, and Lazio. The group delivers a comprehensive spectrum of health and social welfare services through its Hospital and Social/Dependency Care segments, encompassing high-complexity surgery, emergency medicine, clinical and interventional cardiology, rehabilitation for motor, neurological, cardiac, and nutritional needs, extended and intensive care units, centers for coma and persistent vegetative states, psychiatry, and diagnostic services. Emphasizing a patient-centered model, Garofalo Health Care S.p.A. integrates humanization of care, state-of-the-art technologies like robotic-assisted surgery, continuous staff training, intensive research collaborations with universities, and substantial investments in facility modernization to enhance efficiency, patient comfort, and clinical outcomes. With over 2,500 employees and steady revenue growth to approximately €468 million in 2024, it plays a pivotal role in Italy's private healthcare landscape.
11.37% operating margin is respectable but not wide. ROIC at 6.73%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 3.7%, steady but not accelerating.
Net debt of €195M represents 12.6x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
€489M
▲ +3.7% YoY
Net Income (TTM)
€22M
▲ +7.9% YoY
Op. Margin
11.04%
▼ -0.4pp YoY
ROIC
6.73%
▼ -0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€32M
▲ +15.7% YoY
Op. Cash Flow (TTM)
€54M
▼ -14.1% YoY
Net Debt
€195M
Cash & Equiv.
€30M
3Y CAGR: +14.9%
3Y CAGR: -18.7%
Continue Research